Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumor, Adult × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 56 Neoplasm Metastasis 10 Stomach Neoplasms 7 Brain Neoplasms 6 Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Inflammatory Breast Neoplasms 3 HER2-positive Breast Cancer 3 Esophageal Neoplasms 3 Breast Neoplasms, Male 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Meningeal Carcinomatosis 2 Lung Neoplasms 2 Central Nervous System Neoplasms 2 Central Nervous System Diseases 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor, Adult 1 Solid Cancer 1 Sarcoma 1 Recurrence 1 Pathologic Processes 1 Ovarian Neoplasms 1 Nervous System Neoplasms 1 Nervous System Diseases 1 Neoplastic Processes 1 Neoplasms by Site 1

Interventions

pembrolizumab 3 toripalimab 1 spartalizumab 1 sotorasib 1 pazopanib 1 palbociclib 1 abemaciclib 1 Trastuzumab 1 Therapeutics 1 Jupiter 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Fulvestrant 1 EBI-005 1 Cetuximab 1 Catalytic Domain 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04092673 2024-05-21

Zotatifin

Effector Therapeutics

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡